Senolytics in 2025 — Where the Human Evidence Actually Stops

A patient sent me a protocol — dasatinib and quercetin, cycled a few days a month. Dasatinib is a CML drug. They want me to prescribe it for aging. Where do I even start?

Start with the biology, because it is genuinely good. A senescent cell is one that has permanently exited the cell cycle — alive, metabolically active, will not divide, and resists being cleared. That part is textbook.

Why does one stuck cell matter systemically?

Because it secretes. The SASP — senescence-associated secretory phenotype, meaning the cocktail of cytokines, proteases, and growth factors a senescent cell continuously releases — drives local and systemic inflammation and can push neighboring cells into senescence too. Animal data on this is very strong.

And their panel flagged GDF-15 as a marker of senescent cell burden. Is that a real readout?

GDF-15 rises with age and stress and correlates with senescent cell markers in tissue. But it is not a validated senescent cell burden assay. It reflects inflammation from many sources. The report's framing is marketing, not a guideline recommendation.

So what is the human evidence for dasatinib plus quercetin actually clearing senescent cells?

The Mayo group published a small pilot — fifteen patients with diabetic kidney disease — showing reduced p16INK4a and p21 transcript levels in adipose tissue biopsies after one course. That is mechanistic signal, not a clinical endpoint trial. No mortality, no function, no organ outcome.

How small and how short?

Nine completers contributed tissue. Single arm, no comparator. Three-day treatment course, one readout at eleven days. It is a hypothesis-generating study. The authors said so.

There is a larger trial in IPF, right?

Yes — a randomized trial in idiopathic pulmonary fibrosis showed improved physical function at twenty-four weeks. That is the strongest human clinical endpoint data we have. It is one disease, one trial, not replicated in a general aging population.

What about quercetin alone from the supplement side?

Quercetin has senolytic activity in cell culture and mouse models. Human trial data on senescent cell clearance is sparse and mechanistic. No outcome trial. It is sold as a supplement, which means no required efficacy evidence.

And the risk of prescribing dasatinib off-label here?

Pleural effusion, QT prolongation, thrombocytopenia, pulmonary hypertension with chronic use. These are real adverse events from its approved indication. For an unapproved use in a healthy person, that risk-benefit calculation has no trial data to stand on.

So what do I actually tell this patient?

Tell them the biology is real, the early human mechanistic data is real, and that we do not yet have a trial showing that clearing senescent cells improves any outcome they care about — lifespan, function, organ disease. The field may get there. It is not there.

And the GDF-15 panel — do I repeat it to track response?

No. There is no validated threshold, no established response criterion, and no evidence that a falling GDF-15 on a senolytic predicts benefit. Repeating it just medicalizes an unproven intervention.

What's the one thing to hold onto?

The mechanism is compelling and the research is moving fast — but right now the human evidence stops at early-phase mechanistic studies and one small disease-specific trial. Do not prescribe a chemotherapy agent to fill that gap.